Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Luminespib |
Synonyms | |
Therapy Description |
Luminespib (AUY922) inhibits HSP90, resulting in increased tumor cell apoptosis and decreased tumor cell angiogenesis and proliferation (PMID: 25955495, PMID: 18413753). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Luminespib | AUY922|NVP-AUY922 | HSP90 Inhibitor 35 | Luminespib (AUY922) inhibits HSP90, resulting in increased tumor cell apoptosis and decreased tumor cell angiogenesis and proliferation (PMID: 25955495, PMID: 18413753, PMID: 32592377). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB2 G776delinsVC ERBB2 C805S | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). | 30527195 |
JAK2 R867Q | hematologic cancer | decreased response | Luminespib | Preclinical | Actionable | In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Luminespib (AUY922) in culture (PMID: 24398328). | 24398328 |
ERBB2 Y772_A775dup | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195). | 30527195 |
ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). | 30527195 |
EML4 - ALK ALK C1156Y | lung non-small cell carcinoma | no benefit | Luminespib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910). | 26698910 |
ERBB2 G776delinsVC | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195). | 30527195 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01854034 | Phase II | Luminespib | Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | Completed | USA | 0 |
NCT01752400 | Phase II | Luminespib | AUY922 for Advanced ALK-positive NSCLC | Completed | USA | 0 |
NCT01646125 | Phase II | Docetaxel Luminespib Pemetrexed Disodium | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | Terminated | USA | 11 |
NCT01772797 | Phase I | Ceritinib Luminespib | Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer | Completed | USA | 4 |